నైరూప్య

2020 Marker Analysis of Neurology and Brain Disorders April 20-21, 2020 at Bangkok, Thailand

Alireza Heidari

This estimated market analysis is based on probability of approval and sales of products in late stage development, demographic trends and marketing of product. Emerging markets once again helps to boost revenues. CNS therapeutics comprises approximately 15% of total pharmaceutical sales, nearly $30 billion worldwide. Estimated annual economic costs of anxiety disorders, depression, and schizophrenia are $47 billion, $44 billion, and $33 billion per year approximately. The goal of this session is to understand the market Value & Growth of Neurology Drugs, Current economics cost of clinical research and development.